Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors

Cancer Chemother Pharmacol. 2024 Mar 31. doi: 10.1007/s00280-024-04645-9. Online ahead of print.

Authors

Affiliations

¹ Department of Experimental Therapeutics, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-Ku, Tokyo, 104-0045, Japan. nbryamam@ncc.go.jp.
² Department of Experimental Therapeutics, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-Ku, Tokyo, 104-0045, Japan.
³ Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-Chome Chuo-Ku, Tokyo, 103-8324, Japan.

PMID: 38556530
DOI: 10.1007/s00280-024-04645-9

No abstract available

Publication types

Published Erratum